OMEROS CORP Lessee, Operating Lease, Liability, Undiscounted Excess Amount
OMEROS CORP (OMER) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $414.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-03-31
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $414.00K.
- 2024-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $2.72M.
- 2023-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $6.42M.
- 2022-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $9.28M.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2025-12-31 | $414.00K 10-K · filed 2026-03-31 |
| 2024-12-31 | $2.72M 10-K · filed 2025-03-31 |
| 2023-12-31 | $6.42M 10-K · filed 2024-04-01 |
| 2022-12-31 | $9.28M 10-K · filed 2023-03-13 |
| 2021-12-31 | $9.49M 10-K · filed 2022-03-01 |
| 2020-12-31 | $15.83M 10-K · filed 2021-03-01 |
| 2019-12-31 | $19.94M 10-K · filed 2020-03-02 |
| 2019-09-30 | $18.74M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $17.05M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $17.89M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |